Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Mosunetuzumab-axgb
Synonyms
Therapy Description

Lunsumio (mosunetuzumab-axgb) is a bispecific antibody targeting CD20 and CD3, which may result in killing of CD20-positive tumor cells (PMID: 25972002, PMID: 29351372). Lunsumio (mosunetuzumab-axgb) is FDA approved for use in adult patients with relapsed or refractory follicular lymphoma who have received two or more lines of systemic therapy (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Mosunetuzumab-axgb Lunsumio RG7828|BTCT4465A|RO7030816|BTCT-4465A CD20 Antibody 25 CD3 Antibody 108 Lunsumio (mosunetuzumab-axgb) is a bispecific antibody targeting CD20 and CD3, which may result in killing of CD20-positive tumor cells (PMID: 25972002, PMID: 29351372). Lunsumio (mosunetuzumab-axgb) is FDA approved for use in adult patients with relapsed or refractory follicular lymphoma who have received two or more lines of systemic therapy (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06569680 Phase II Mosunetuzumab-axgb Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma Recruiting USA 0
NCT05389293 Phase II Mosunetuzumab-axgb A Study of Mosunetuzumab in People With Follicular Lymphoma Recruiting USA 0
NCT03671018 Phase I Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Polatuzumab vedotin-piiq + Rituximab Bendamustine + Obinutuzumab Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Mosunetuzumab-axgb Obinutuzumab Tocilizumab A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma Active, not recruiting USA | GBR | ESP | CAN | BEL 0
NCT05961696 Phase I Mosunetuzumab-axgb A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Withdrawn USA 0
NCT06337318 Phase III Mosunetuzumab-axgb Rituximab Hyaluronidase + Rituximab Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma Recruiting USA 0
NCT04889716 Phase II Glofitamab-gxbm + Obinutuzumab Mosunetuzumab-axgb CAR-T Followed by Bispecific Antibodies Recruiting USA 0
NCT05412290 Phase I Mosunetuzumab-axgb Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma Recruiting USA 0
NCT05886036 Phase II Mosunetuzumab-axgb Rituximab + Rituximab Hyaluronidase Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Recruiting USA | CAN 0
NCT06828991 Phase II Mosunetuzumab-axgb A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients with Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of CtDNA (circulating Tumor DNA) At the End of Treatment with Pola-R-mini-CHP (GOLD) Not yet recruiting USA 0
NCT06442475 Phase II Mosunetuzumab-axgb Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma Recruiting USA 0
NCT05464329 Phase I Mosunetuzumab-axgb Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma Recruiting USA 0
NCT05633615 Phase II Cyclophosphamide + Fludarabine axicabtagene ciloleucel + Lisocabtagene maraleucel + Tisagenlecleucel Polatuzumab vedotin-piiq Mosunetuzumab-axgb Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Recruiting USA 0
NCT05849857 Phase II Mosunetuzumab-axgb Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries (MERLIN) Recruiting NOR | FIN 0


Additional content available in Icon for CKB-BoostCKB BOOST